Revolution Medicines Updates Zoldonrasib Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy RVMD?
Revolution Medicines announced updated Phase 1 clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer, NSCLC. Results were highlighted in the official press program at the American Association for Cancer Research, AACR. Zoldonrasib was generally well tolerated and demonstrated a safety profile consistent with previously reported findings. Treatment-related adverse events of any grade occurring in at least 15% of patients were nausea, vomiting, diarrhea, and rash. The majority of TRAEs were Grade 1 in severity. Grade 3 TRAEs occurred in 13% of patients and resolved following dose interruption; TRAEs led to treatment discontinuation in 5% of patients. No Grade 4 or Grade 5 TRAEs were observed. Zoldonrasib demonstrated a favorable mean dose intensity of 94%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 134.480
Low
67.00
Averages
86.00
High
147.00
Current: 134.480
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revolution Medicines Updates Clinical Data on Daraxonrasib for Pancreatic Cancer
- Clinical Trial Update: Revolution Medicines has updated clinical data from two Phase 1/2 trials of Daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma patients, demonstrating manageable safety and tolerability, supporting further evaluation in first-line treatment.
- Combination Therapy Results: In the RMC-GI-102 trial, patients receiving Daraxonrasib combined with gemcitabine and nab-paclitaxel showed a confirmed objective response rate (ORR) of 58%, indicating significant antitumor activity, with a 6-month progression-free survival (PFS) estimate of 84%.
- Monotherapy Performance: In the RMC-6236-001 trial, Daraxonrasib monotherapy yielded an ORR of 47% and a disease control rate of 92%, with a 6-month PFS estimate of 71%, highlighting its potential in treating previously untreated RAS-mutant metastatic pancreatic cancer patients.
- Future Presentation Plans: The company plans to present the latest data from both the combination and monotherapy cohorts at the American Association for Cancer Research Annual Meeting on April 21, 2026, further validating the application prospects of Daraxonrasib in this high-mortality cancer.
See More
Revolution Medicines Releases Clinical Data on Daraxonrasib
- Clinical Trial Updates: Revolution Medicines presented updated clinical data on daraxonrasib at the AACR Annual Meeting, demonstrating manageable safety and early signs of durable antitumor activity in previously untreated metastatic pancreatic ductal adenocarcinoma patients, supporting further evaluation in first-line treatment.
- Combination Therapy Efficacy: In the RMC-GI-102 trial, 40 patients received daraxonrasib combined with gemcitabine and nab-paclitaxel, achieving a 58% objective response rate, indicating the potential of this combination in treating difficult-to-manage pancreatic cancer.
- Monotherapy Performance: In the RMC-6236-001 trial, daraxonrasib monotherapy showed a 47% objective response rate and a 92% disease control rate, highlighting its effectiveness in previously untreated patients.
- Future Research Directions: Daraxonrasib is currently being evaluated in four global Phase 3 clinical trials, showcasing its broad application potential in treating RAS-mutant cancers, particularly in pancreatic and non-small cell lung cancer.
See More
Revolution Medicines Presents Phase 3 Trial Results for Daraxonrasib
- Clinical Trial Results: Revolution Medicines presented results from the RASolute 302 trial at the ASCO Annual Meeting, demonstrating that daraxonrasib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma, thereby strengthening the company's competitive position in oncology.
- Drug Design Advantages: As an oral RAS(ON) multi-selective inhibitor, daraxonrasib has received Breakthrough Therapy and Orphan Drug Designations from the FDA, indicating its potential value in treating patients with specific RAS mutations, which may attract increased investor interest.
- Global Clinical Reach: The RASolute 302 trial enrolled patients globally, covering a range of RAS variants, showcasing the company's capability to expand in international markets, with successful clinical outcomes likely to drive drug approval and enhance market share.
- Future Growth Potential: With daraxonrasib being evaluated in additional clinical trials, Revolution Medicines' R&D pipeline indicates strong growth potential, particularly in the treatment of RAS-mutant cancers, which could lead to long-term revenue growth for the company.
See More
Revolution Medicines Releases Updated Clinical Data for Zoldonrasib
- Clinical Trial Progress: Revolution Medicines presented updated Phase 1 clinical data for zoldonrasib at the AACR Annual Meeting, involving 40 patients with KRAS G12D non-small cell lung cancer, demonstrating a 52% objective response rate, indicating significant clinical activity and potential new treatment options for patients.
- Safety Analysis: Among patients treated with 1200 mg of zoldonrasib once daily, 43% experienced nausea, 33% vomiting, and 30% diarrhea, with most adverse events being Grade 1, showcasing a favorable safety profile that supports further clinical development.
- Survival Rate Data: The treatment yielded an 11.1-month median progression-free survival and a 73% 12-month survival rate among treated patients, suggesting zoldonrasib's potential efficacy in KRAS G12D non-small cell lung cancer, which could alter the treatment landscape in this area.
- Market Potential: With approximately 61,000 new patients diagnosed with RAS G12D cancers annually, the development of zoldonrasib not only addresses significant unmet medical needs but also presents substantial commercial opportunities for Revolution Medicines in the competitive oncology market.
See More
Revolution Medicines Closes Upsized Offering of 12.1 Million Shares
- Significant Financing: Revolution Medicines successfully completed an upsized offering of 12,147,887 shares of common stock at $142 per share, generating approximately $2.225 billion in gross proceeds, reflecting strong market confidence in its targeted therapies for RAS-addicted cancers.
- Convertible Notes Issuance: The company also issued $500 million in 0.50% convertible senior notes due 2033, with an initial conversion price of about $198.80, representing a 40% premium over the offering price, providing flexibility for future financing.
- Clear Use of Proceeds: The estimated net proceeds of approximately $2.137 billion will be allocated to research and development, potential commercialization of product candidates, and general corporate expenses, indicating the company's commitment to future product development and strategic planning.
- Positive Market Reaction: The offering was facilitated by prominent investment banks like J.P. Morgan, reflecting investor optimism about Revolution Medicines' prospects in oncology, which may drive an increase in the company's stock price.
See More
Revolution Medicines Raises Approximately $1.5 Billion in Public Offering
- Upsized Offering: Revolution Medicines successfully priced a public offering of 10.56 million shares at $142 each, raising approximately $1.5 billion, significantly up from the initial plan of $750 million, indicating strong market demand for its stock.
- Convertible Notes Issuance: The company also issued $500 million in convertible senior notes with a 0.50% annual interest rate, maturing on May 1, 2033, which is expected to provide additional funding to support R&D and commercialization efforts.
- Conversion Price Premium: The initial conversion price of approximately $198.80 represents a 40% premium over the public offering price, reflecting investor confidence in the company's growth potential and likely attracting more investor interest.
- Clear Use of Proceeds: Revolution Medicines plans to utilize the raised funds for general corporate purposes, including R&D, potential commercialization, administrative costs, and capital expenditures, demonstrating a clear strategic plan for future growth.
See More
Revolution Medicines Updates Clinical Data on Daraxonrasib for Pancreatic Cancer
- Clinical Trial Update: Revolution Medicines has updated clinical data from two Phase 1/2 trials of Daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma patients, demonstrating manageable safety and tolerability, supporting further evaluation in first-line treatment.
- Combination Therapy Results: In the RMC-GI-102 trial, patients receiving Daraxonrasib combined with gemcitabine and nab-paclitaxel showed a confirmed objective response rate (ORR) of 58%, indicating significant antitumor activity, with a 6-month progression-free survival (PFS) estimate of 84%.
- Monotherapy Performance: In the RMC-6236-001 trial, Daraxonrasib monotherapy yielded an ORR of 47% and a disease control rate of 92%, with a 6-month PFS estimate of 71%, highlighting its potential in treating previously untreated RAS-mutant metastatic pancreatic cancer patients.
- Future Presentation Plans: The company plans to present the latest data from both the combination and monotherapy cohorts at the American Association for Cancer Research Annual Meeting on April 21, 2026, further validating the application prospects of Daraxonrasib in this high-mortality cancer.
See More
Revolution Medicines Releases Clinical Data on Daraxonrasib
- Clinical Trial Updates: Revolution Medicines presented updated clinical data on daraxonrasib at the AACR Annual Meeting, demonstrating manageable safety and early signs of durable antitumor activity in previously untreated metastatic pancreatic ductal adenocarcinoma patients, supporting further evaluation in first-line treatment.
- Combination Therapy Efficacy: In the RMC-GI-102 trial, 40 patients received daraxonrasib combined with gemcitabine and nab-paclitaxel, achieving a 58% objective response rate, indicating the potential of this combination in treating difficult-to-manage pancreatic cancer.
- Monotherapy Performance: In the RMC-6236-001 trial, daraxonrasib monotherapy showed a 47% objective response rate and a 92% disease control rate, highlighting its effectiveness in previously untreated patients.
- Future Research Directions: Daraxonrasib is currently being evaluated in four global Phase 3 clinical trials, showcasing its broad application potential in treating RAS-mutant cancers, particularly in pancreatic and non-small cell lung cancer.
See More
Revolution Medicines Presents Phase 3 Trial Results for Daraxonrasib
- Clinical Trial Results: Revolution Medicines presented results from the RASolute 302 trial at the ASCO Annual Meeting, demonstrating that daraxonrasib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma, thereby strengthening the company's competitive position in oncology.
- Drug Design Advantages: As an oral RAS(ON) multi-selective inhibitor, daraxonrasib has received Breakthrough Therapy and Orphan Drug Designations from the FDA, indicating its potential value in treating patients with specific RAS mutations, which may attract increased investor interest.
- Global Clinical Reach: The RASolute 302 trial enrolled patients globally, covering a range of RAS variants, showcasing the company's capability to expand in international markets, with successful clinical outcomes likely to drive drug approval and enhance market share.
- Future Growth Potential: With daraxonrasib being evaluated in additional clinical trials, Revolution Medicines' R&D pipeline indicates strong growth potential, particularly in the treatment of RAS-mutant cancers, which could lead to long-term revenue growth for the company.
See More
Revolution Medicines Releases Updated Clinical Data for Zoldonrasib
- Clinical Trial Progress: Revolution Medicines presented updated Phase 1 clinical data for zoldonrasib at the AACR Annual Meeting, involving 40 patients with KRAS G12D non-small cell lung cancer, demonstrating a 52% objective response rate, indicating significant clinical activity and potential new treatment options for patients.
- Safety Analysis: Among patients treated with 1200 mg of zoldonrasib once daily, 43% experienced nausea, 33% vomiting, and 30% diarrhea, with most adverse events being Grade 1, showcasing a favorable safety profile that supports further clinical development.
- Survival Rate Data: The treatment yielded an 11.1-month median progression-free survival and a 73% 12-month survival rate among treated patients, suggesting zoldonrasib's potential efficacy in KRAS G12D non-small cell lung cancer, which could alter the treatment landscape in this area.
- Market Potential: With approximately 61,000 new patients diagnosed with RAS G12D cancers annually, the development of zoldonrasib not only addresses significant unmet medical needs but also presents substantial commercial opportunities for Revolution Medicines in the competitive oncology market.
See More
Revolution Medicines Closes Upsized Offering of 12.1 Million Shares
- Significant Financing: Revolution Medicines successfully completed an upsized offering of 12,147,887 shares of common stock at $142 per share, generating approximately $2.225 billion in gross proceeds, reflecting strong market confidence in its targeted therapies for RAS-addicted cancers.
- Convertible Notes Issuance: The company also issued $500 million in 0.50% convertible senior notes due 2033, with an initial conversion price of about $198.80, representing a 40% premium over the offering price, providing flexibility for future financing.
- Clear Use of Proceeds: The estimated net proceeds of approximately $2.137 billion will be allocated to research and development, potential commercialization of product candidates, and general corporate expenses, indicating the company's commitment to future product development and strategic planning.
- Positive Market Reaction: The offering was facilitated by prominent investment banks like J.P. Morgan, reflecting investor optimism about Revolution Medicines' prospects in oncology, which may drive an increase in the company's stock price.
See More
Revolution Medicines Raises Approximately $1.5 Billion in Public Offering
- Upsized Offering: Revolution Medicines successfully priced a public offering of 10.56 million shares at $142 each, raising approximately $1.5 billion, significantly up from the initial plan of $750 million, indicating strong market demand for its stock.
- Convertible Notes Issuance: The company also issued $500 million in convertible senior notes with a 0.50% annual interest rate, maturing on May 1, 2033, which is expected to provide additional funding to support R&D and commercialization efforts.
- Conversion Price Premium: The initial conversion price of approximately $198.80 represents a 40% premium over the public offering price, reflecting investor confidence in the company's growth potential and likely attracting more investor interest.
- Clear Use of Proceeds: Revolution Medicines plans to utilize the raised funds for general corporate purposes, including R&D, potential commercialization, administrative costs, and capital expenditures, demonstrating a clear strategic plan for future growth.
See More
